Global Pompe Disease Drugs Market Insights, Forecast to 2025

Description

The global Pompe Disease Drugs market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Pompe Disease Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Pompe Disease Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Pompe Disease Drugs in these regions.
This research report categorizes the global Pompe Disease Drugs market by top players/brands, region, type and end user. This report also studies the global Pompe Disease Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Genzyme(A Sanofi Company)
BioMarin
Amicus
Audentes
EpiVax
Oxyrane
Sangamo
Valerion Therapeutics

Market size by Product
Liver Drugs
Heart Drugs
Muscle Drugs
Market size by End User
Hospital
Clinic
Other

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Pompe Disease Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Pompe Disease Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Pompe Disease Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Pompe Disease Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Pompe Disease Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Pompe Disease Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

TABLE OF CONTENT

Table of Contents

1 Study Coverage
1.1 Pompe Disease Drugs Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Pompe Disease Drugs Market Size Growth Rate by Product
1.4.2 Liver Drugs
1.4.3 Heart Drugs
1.4.4 Muscle Drugs
1.5 Market by End User
1.5.1 Global Pompe Disease Drugs Market Size Growth Rate by End User
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Pompe Disease Drugs Market Size
2.1.1 Global Pompe Disease Drugs Revenue 2014-2025
2.1.2 Global Pompe Disease Drugs Sales 2014-2025
2.2 Pompe Disease Drugs Growth Rate by Regions
2.2.1 Global Pompe Disease Drugs Sales by Regions
2.2.2 Global Pompe Disease Drugs Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Pompe Disease Drugs Sales by Manufacturers
3.1.1 Pompe Disease Drugs Sales by Manufacturers
3.1.2 Pompe Disease Drugs Sales Market Share by Manufacturers
3.1.3 Global Pompe Disease Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Pompe Disease Drugs Revenue by Manufacturers
3.2.1 Pompe Disease Drugs Revenue by Manufacturers (2014-2019)
3.2.2 Pompe Disease Drugs Revenue Share by Manufacturers (2014-2019)
3.3 Pompe Disease Drugs Price by Manufacturers
3.4 Pompe Disease Drugs Manufacturing Base Distribution, Product Types
3.4.1 Pompe Disease Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Pompe Disease Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Pompe Disease Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global Pompe Disease Drugs Sales by Product
4.2 Global Pompe Disease Drugs Revenue by Product
4.3 Pompe Disease Drugs Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global Pompe Disease Drugs Breakdown Data by End User

6 North America
6.1 North America Pompe Disease Drugs by Countries
6.1.1 North America Pompe Disease Drugs Sales by Countries
6.1.2 North America Pompe Disease Drugs Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Pompe Disease Drugs by Product
6.3 North America Pompe Disease Drugs by End User

7 Europe
7.1 Europe Pompe Disease Drugs by Countries
7.1.1 Europe Pompe Disease Drugs Sales by Countries
7.1.2 Europe Pompe Disease Drugs Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Pompe Disease Drugs by Product
7.3 Europe Pompe Disease Drugs by End User

8 Asia Pacific
8.1 Asia Pacific Pompe Disease Drugs by Countries
8.1.1 Asia Pacific Pompe Disease Drugs Sales by Countries
8.1.2 Asia Pacific Pompe Disease Drugs Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Pompe Disease Drugs by Product
8.3 Asia Pacific Pompe Disease Drugs by End User

9 Central & South America
9.1 Central & South America Pompe Disease Drugs by Countries
9.1.1 Central & South America Pompe Disease Drugs Sales by Countries
9.1.2 Central & South America Pompe Disease Drugs Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Pompe Disease Drugs by Product
9.3 Central & South America Pompe Disease Drugs by End User

10 Middle East and Africa
10.1 Middle East and Africa Pompe Disease Drugs by Countries
10.1.1 Middle East and Africa Pompe Disease Drugs Sales by Countries
10.1.2 Middle East and Africa Pompe Disease Drugs Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Pompe Disease Drugs by Product
10.3 Middle East and Africa Pompe Disease Drugs by End User

11 Company Profiles
11.1 Genzyme(A Sanofi Company)
11.1.1 Genzyme(A Sanofi Company) Company Details
11.1.2 Company Business Overview
11.1.3 Genzyme(A Sanofi Company) Pompe Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Genzyme(A Sanofi Company) Pompe Disease Drugs Products Offered
11.1.5 Genzyme(A Sanofi Company) Recent Development
11.2 BioMarin
11.2.1 BioMarin Company Details
11.2.2 Company Business Overview
11.2.3 BioMarin Pompe Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
11.2.4 BioMarin Pompe Disease Drugs Products Offered
11.2.5 BioMarin Recent Development
11.3 Amicus
11.3.1 Amicus Company Details
11.3.2 Company Business Overview
11.3.3 Amicus Pompe Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Amicus Pompe Disease Drugs Products Offered
11.3.5 Amicus Recent Development
11.4 Audentes
11.4.1 Audentes Company Details
11.4.2 Company Business Overview
11.4.3 Audentes Pompe Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Audentes Pompe Disease Drugs Products Offered
11.4.5 Audentes Recent Development
11.5 EpiVax
11.5.1 EpiVax Company Details
11.5.2 Company Business Overview
11.5.3 EpiVax Pompe Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
11.5.4 EpiVax Pompe Disease Drugs Products Offered
11.5.5 EpiVax Recent Development
11.6 Oxyrane
11.6.1 Oxyrane Company Details
11.6.2 Company Business Overview
11.6.3 Oxyrane Pompe Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Oxyrane Pompe Disease Drugs Products Offered
11.6.5 Oxyrane Recent Development
11.7 Sangamo
11.7.1 Sangamo Company Details
11.7.2 Company Business Overview
11.7.3 Sangamo Pompe Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Sangamo Pompe Disease Drugs Products Offered
11.7.5 Sangamo Recent Development
11.8 Valerion Therapeutics
11.8.1 Valerion Therapeutics Company Details
11.8.2 Company Business Overview
11.8.3 Valerion Therapeutics Pompe Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Valerion Therapeutics Pompe Disease Drugs Products Offered
11.8.5 Valerion Therapeutics Recent Development

12 Future Forecast
12.1 Pompe Disease Drugs Market Forecast by Regions
12.1.1 Global Pompe Disease Drugs Sales Forecast by Regions 2019-2025
12.1.2 Global Pompe Disease Drugs Revenue Forecast by Regions 2019-2025
12.2 Pompe Disease Drugs Market Forecast by Product
12.2.1 Global Pompe Disease Drugs Sales Forecast by Product 2019-2025
12.2.2 Global Pompe Disease Drugs Revenue Forecast by Product 2019-2025
12.3 Pompe Disease Drugs Market Forecast by End User
12.4 North America Pompe Disease Drugs Forecast
12.5 Europe Pompe Disease Drugs Forecast
12.6 Asia Pacific Pompe Disease Drugs Forecast
12.7 Central & South America Pompe Disease Drugs Forecast
12.8 Middle East and Africa Pompe Disease Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Pompe Disease Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

Choose License Type

Checkout Inquiry Sample